全部
  • 全部
  • 标题
  • 关键词
  • 摘要
共计条
高级检索
详细信息
Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion

    作者

    Li, FJ;Sun, M;Guo, JL;Ma, AH;Zhao, BJ

    作者单位

    [Li, Fengjiao; Zhao, Bojun] Shandong Univ, Dept Ophthalmol, Shandong Prov Hosp, Jinan, Shandong, Peoples R China.;-;[Sun, Ming] Jinan Matern & Child Care Hosp, Dept Ophthalmol, Jinan, Shandong, Peoples R China.;-;[Guo, Jianlian] Jinan Eighth Peoples Hosp, Dept Ophthalmol, Jinan, Shandong, Peoples R China.;-;[Ma, Aihua] Shandong Univ, Dept Pediat, Shandong Prov Hosp, 324 Jingwu Rd, Jinan 250021, Shandong, Peoples R China.

    摘要

    Purpose: To confirm the therapeutic efficacy of conbercept for the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO).Methods: In this prospective, randomized, and comparative study, patients were randomized and divided into conbercept (n = 18) and ranibizumab (n = 17) groups. After an initial intravitreal injection of either conbercept or ranibizumab, a pro re nata (PRN) strategy was adopted based on loss of visual acuity (VA) or increase in central macular thickness (CMT).Results: All patients were followed for 6 months. Baseline best-corrected visual acuities (BCVAs) were 0.67 0.37 and 0.511 +/- 0.23 logMAR in the conbercept and ranibizumab groups, respectively (p = 0.087, t-test). Baseline CMTs were 512.5 +/- 115.22 and 491.23 +/- 114.72 mu m in the conbercept and ranibizumab groups, respectively (p = 0.993, t-test). Significant improvements in BCVA and reduction of CMT were observed in both groups at each follow-up visit and compared to baseline values (p < 0.05, t-test). No significant differences in improvement of BCVA (p > 0.05, t-test) or reduction of CMT (p > 0.05, t-test) were noted in either group. Mean numbers of injections were 2.28 +/- 0.96 and 2.65 +/- 1.17 for the conbercept and ranibizumab groups, respectively (p = 0.478, t-test), with no statistically significant differences between the two groups.Conclusion: Intravitreal injection of conbercept is shown to be safe and effective for the treatment of ME secondary to BRVO, based on 6-month follow-up data.

    关键词

    ENDOTHELIAL GROWTH-FACTOR; EFFICACY
基本信息

  • 所属机构:眼科门诊

    归属医师: 马爱华 赵博军 李凤娇

    PMID：28441077

    UT：000407080800015

    刊名:CURRENT EYE RESEARCH

    年，卷(期):2017年42卷8期

    页码：1174-1178

    DOI：10.1080/02713683.2017.1285943

    附件：

    收录:   SCIE